Sei Investments Co. Increases Stake in Biogen Inc. $BIIB

Sei Investments Co. grew its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 20.2% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 71,513 shares of the biotechnology company’s stock after purchasing an additional 12,017 shares during the quarter. Sei Investments Co.’s holdings in Biogen were worth $13,112,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in BIIB. Reflection Asset Management purchased a new stake in Biogen during the 4th quarter valued at $25,000. WPG Advisers LLC grew its holdings in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 117 shares during the last quarter. First Horizon Corp purchased a new position in shares of Biogen in the fourth quarter valued at about $30,000. WFA of San Diego LLC bought a new position in shares of Biogen during the second quarter valued at about $32,000. Finally, Root Financial Partners LLC raised its stake in shares of Biogen by 198.4% during the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 123 shares during the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q2 results exceeded expectations: Biogen reported approximately $2.74 billion in revenue, up 3.4% year over year and above the $2.46 billion consensus estimate. Adjusted EPS of $3.60 also topped forecasts near $2.94, supported by stronger rare-disease and newer-product sales. Biogen beats quarterly estimates as newer drugs fuel growth
• Positive Sentiment: Growth portfolio is offsetting legacy weakness: Revenue from Biogen’s Growth Portfolio rose 24% to about $1.06 billion, surpassing its legacy multiple sclerosis portfolio. The Apellis acquisition added sales from SYFOVRE and EMPAVELI, while products including SKYCLARYS and ZURZUVAE contributed to momentum. Biogen’s Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
• Positive Sentiment: Analyst sentiment improved: TD Cowen raised its price target to $225 and assigned a Buy rating, while Morgan Stanley lifted its target to $231 and maintained Equal Weight. Wedbush also raised its target to $215, and Piper Sandler reaffirmed its Buy rating. Analyst target updates
• Neutral Sentiment: 2026 outlook was updated: Biogen expects full-year non-GAAP EPS of $12 to $13 and mid-single-digit revenue growth. The revenue outlook benefits from the newer portfolio, but the EPS range is below the roughly $13.45 analyst consensus, partly reflecting acquisition-related costs. Biogen beats quarterly estimates as newer drugs fuel growth
• Negative Sentiment: Reported profitability deteriorated materially: GAAP net income fell to $97.5 million from $634.8 million a year earlier, while diluted EPS dropped to $0.66 from $4.33. Legacy multiple sclerosis sales also remained under pressure, and Leqembi sales narrowly missed expectations. Biogen profitability compression

Biogen Price Performance

Shares of NASDAQ BIIB opened at $207.93 on Friday. Biogen Inc. has a 1 year low of $124.56 and a 1 year high of $219.72. The stock has a market capitalization of $30.70 billion, a P/E ratio of 36.80 and a beta of 0.16. The company’s 50-day moving average is $201.05 and its 200 day moving average is $190.52. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.87 and a quick ratio of 2.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, beating the consensus estimate of $2.94 by $0.66. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The business had revenue of $2.74 billion for the quarter, compared to analysts’ expectations of $2.46 billion. During the same period in the previous year, the firm posted $5.47 EPS. The business’s revenue was up 3.4% on a year-over-year basis. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, sell-side analysts expect that Biogen Inc. will post 12.38 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Jefferies Financial Group reissued a “buy” rating on shares of Biogen in a research note on Monday, July 13th. Truist Financial upgraded Biogen from a “hold” rating to a “buy” rating and increased their price objective for the stock from $190.00 to $235.00 in a report on Monday, July 13th. Argus upgraded Biogen to a “hold” rating in a research report on Thursday, April 9th. Royal Bank Of Canada reduced their target price on Biogen from $242.00 to $240.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Wedbush upped their target price on Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $223.36.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.